# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Cantor Fitzgerald analyst Prakhar Agrawal reiterates Structure Therapeutics (NASDAQ:GPCR) with a Overweight and maintains $6...
Cantor Fitzgerald analyst Prakhar Agrawal reiterates Structure Therapeutics (NASDAQ:GPCR) with a Overweight and maintains $6...
Cantor Fitzgerald analyst Prakhar Agrawal reiterates Structure Therapeutics (NASDAQ:GPCR) with a Overweight and maintains $6...
Cantor Fitzgerald analyst Prakhar Agrawal reiterates Structure Therapeutics (NASDAQ:GPCR) with a Overweight and maintains $6...
JMP Securities analyst Jonathan Wolleben maintains Structure Therapeutics (NASDAQ:GPCR) with a Market Outperform and lowers ...
Structure Therapeutics (NASDAQ:GPCR) reported quarterly losses of $(0.18) per share which beat the analyst consensus estimate o...
Eli Lilly, Novo Nordisk, Viking Therapeutics, and Structure Therapeutics shares are down following Roche's promising CT-996...